Clinical Trial: Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06858839) titled 'Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight' on Feb. 28.

Brief Summary: The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Study Start Date: March 17

Study Type: INTERVENTIONAL

Condition: Obesity

Intervention: DRUG: Maridebart Cafraglutide

Maridebart cafraglutide will be administered SC.

DRUG: Placebo

Placebo will be administered SC.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Amgen

Published by HT Digital Content Services with permission from He...